The "Global Cancer Vaccines Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
The Global Cancer Vaccines market is growing at a CAGR of 18.7% from 2018 to 2026.
Cancer vaccines are a kind of biological treatment that avoids and heals different sorts of cancer diseases, for example, cervical cancer, prostate cancer, lung cancer, breast cancer, and others. They are designed specifically to recognize and decrease the growth of cancer cells by the immune system. Besides, cancer vaccines are expected to decrease the prevalence and incidence rate of cancer. Factors for example, increasing occurrence of human papilloma virus (HPV) infections and high government investments for the advancement of these vaccines are driving the market growth. Though, longer time span required for manufacturing a single product and high cost for developing these vaccines are projected to inhibit the growth of the market.
By treatment method, preventive vaccine segment acquired significant growth in the market as they are the intended to prevent cancer in healthy people. These vaccines work by preventing infectious agents that cause or contribute to the development of cancer. Most of the preventive vaccines stimulate the production of antibodies, which bind to specific targeted microbes and block their ability to cause infection.
The key vendors mentioned are Aduro BioTech Inc, Astellas Pharma Inc, AstraZeneca PLC, Bavarian Nordic, Bharat Biotech, Bristol-Myers Squibb, Dendreon, Dynavax Technologies Corporation, Emergent Biosolutions, Galena Biopharma, Gamma Vaccines Pty Limited, GlaxoSmithKline, Gritstone Oncology, ImmunoBiology Ltd, Immunomic Therapeutics Inc, Merck & Co Inc, Novavax Inc, OSE Immunotherapeutics, PaxVax Corporation, Prokarium, Sanofi, Sinovac Biotech Ltd and VBI Vaccines Inc.
Key Questions Answered in this Report:
Key Topics Covered:
1 Market Synopsis
2 Research Outline
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Cancer Vaccines Market, By Treatment Method
5.1 Introduction
5.2 Therapeutic Vaccine
5.3 Preventive Vaccine
6 Global Cancer Vaccines Market, By Technology
6.1 Introduction
6.2 Antigen/Adjuvant Cancer Vaccines
6.3 Dendritic Cells (DC) Cancer Vaccines
6.4 Recombinant Cancer Vaccines
6.5 Viral Vector and DNA Cancer Vaccines
6.6 Whole Cell Cancer Vaccines
7 Global Cancer Vaccines Market, By Type
7.1 Introduction
7.2 Conjugate Vaccines
7.3 Inactivated Vaccines
7.4 Live Attenuated Vaccines
7.5 Recombinant Vector Vaccines
7.6 Subunit Vaccines
7.7 Viral Vector and DNA Vaccines
8 Global Cancer Vaccines Market, By Application
8.1 Introduction
8.2 Breast cancer
8.3 Cervical Cancer
8.4 Lung cancer
8.5 Prostate Cancer
9 Global Cancer Vaccines Market, By End User
9.1 Introduction
9.2 Adults
9.3 Pediatrics
10 Global Cancer Vaccines Market, By Geography
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 South America
10.5 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 Aduro BioTech Inc
12.2 Astellas Pharma Inc
12.3 AstraZeneca PLC
12.4 Bavarian Nordic
12.5 Bharat Biotech
12.6 Bristol-Myers Squibb
12.7 Dendreon
12.8 Dynavax Technologies Corporation
12.9 Emergent Biosolutions
12.10 Galena Biopharma
12.11 Gamma Vaccines Pty Limited
12.12 GlaxoSmithKline
12.13 Gritstone Oncology
12.14 ImmunoBiology Ltd
12.15 Immunomic Therapeutics Inc
12.16 Merck & Co Inc
12.17 Novavax Inc
12.18 OSE Immunotherapeutics
12.19 PaxVax Corporation
12.20 Prokarium
12.21 Sanofi
12.22 Sinovac Biotech Ltd
12.23 VBI Vaccines Inc
For more information about this report visit https://www.researchandmarkets.com/r/avgl7v
These press releases may also interest you
|